Exome+
Proprietary sequencing assay enabling Sequence Once, Query Often model
Platform · Cloud SaaSCompany source
Company profile
About Helix
Helix is the leading enterprise genomics platform that transforms health systems and enables life science organizations to leverage the power of genomics across their enterprise, creating strategic value and fueling future growth. The company brings together every component of genomic medicine into a single, unified platform, serving providers, patients, health systems, health plans, and life sciences organizations. Helix operates the Helix Research Network®, North America's largest precision health network, which accelerates genomic discoveries and translates them into real-world clinical impact. The platform offers comprehensive solutions including population genomics, clinical testing through Helix Diagnostics, and research and discovery capabilities via Helix GenoSphere™, which provides access to the largest clinico-genomic database with 13+ years of longitudinal medical records. The company's mission is to empower every person to improve their life through DNA by weaving genomics into the fabric of healthcare. Helix has sequenced over 500,000 exomes and serves more than 1.5 million lives in enterprise genomics programs. The platform simplifies the complexity of genomic medicine through easy test ordering, clinical decision support, and EHR integration, enabling healthcare providers to focus on patient care while leveraging the power of precision medicine at population scale.
Company description Helix official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Helix?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- genetic diseases
- Inherited Cardiovascular Diseases
Who it serves
- Health Plans
- Health Systems
- Life Sciences
- Patients
- Providers
Deployment & integration
Cloud Saas deployment with recorded integration context.
Recorded integration context: EHR systems.
Geographic context
MarketsNorth America · United States
Company sourceOfficial website
Company milestones
Platform expansion
Multi-year agreement with Alnylam announced March 2026 for precision medicine development; Partnership with Mawi DNA Technologies announced February 2026 to expand non-invasive genomic sample collection; Received 2026 BIG Innovation Award in January 2026
Partnerships
Recorded partners
- Alnylam
- Mawi DNA Technologies
- WellSpan
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Genomic Advantage
Reduce plan costs and drive growth for health plans with genomics
Platform · Cloud SaaSCompany source
Helix Diagnostics
Comprehensive clinical genetic testing with seamless ordering and EHR integration
Platform · Cloud SaaSCompany source
Helix GenoSphere
Largest clinico-genomic database with 13+ years of longitudinal medical records
Platform · Cloud SaaSCompany source
Helix Research Network
North America's largest precision health network for genomic discoveries and clinical impact
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Networks of sexually dimorphic neurons that regulate social behaviors in Drosophila.Current biology : CB · Sep 3, 2026
Highly Efficient Postprocessing Cleaning of van der Waals Devices.Nano letters · Sep 2, 2026
Genome mining reveals an architecturally expanded pyoluteorin-associated biosynthetic gene cluster and a divergent flavin-dependent halogenase-like sequence in deep-sea Pseudomonas Aeruginosa from the Gulf of Guinea.Antonie van Leeuwenhoek · Sep 1, 2026
Peripartum Management for Patients Receiving Medication for Opioid Use Disorder.Anesthesiology clinics · Sep 1, 2026
The guardian paradox: DNA damage response overactivation as an integrative driver of aging - a tumor suppressor-negative regulator framework.Aging · Aug 31, 2026
Unveiling crosstalk regulations within the polyamine pathway and between polyamine and purine pathways in Aedes aegypti females.Insect biochemistry and molecular biology · Aug 28, 2026
Clinical validation
Clinical-trial records
A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX)NCT06948773 · Mentioned · ACTIVE NOT RECRUITING
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsNCT07185997 · Mentioned · RECRUITING
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaNCT06676319 · Mentioned · ACTIVE NOT RECRUITING
Cough Reduction in IPF With Nalbuphine ERNCT05964335 · Mentioned · COMPLETED
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With AsthmaNCT06609239 · Mentioned · ENROLLING BY INVITATION
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypeNCT07190209 · Mentioned · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Lives saved and life years saved
Calculated using published cost-effectiveness model for population-level planning from genomic programs
Multi-institutional partners (unnamed)
Variant of Uncertain Significance (VUS) resolution through population-scale real-world evidence
45% of VUS carriers can have variant status resolved; 96% of reclassified variants confirmed Benign; 9% increase in pathogenic calls; 60% projected VUS resolution at 2M participants
Academic Health System Partner (unnamed)
Enterprise precision medicine strategy implementation over three years
PGx turnaround dropped from 1 week to 80 seconds; 9% of patients new to health system; 20% of participants re-engaged after 3+ years; $13.5M in grant funding potential
WellSpan
Implementation of inherited cardiovascular disease genomics program
Lives saved and years of life saved tracked monthly through genomic programs
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from Helix
Recent articles published on Helix's official website.
Why the Best Patient Recruitment Starts with the Genome
Read on HelixFinding the Right Population Faster: Inside Helix's GenoSphere™ and Cohort Builder
Read on HelixWhen Genetics Are Ignored at the Pharmacy
Read on HelixBetter Data, Better Diagnoses: The Power of Shared Genomic Data
Read on HelixHow Record Q4 2025 Growth in GenoSphere Clinico-genomic Cohorts Is Advancing Precision Medicine Research
Read on Helix07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.